Ambrx granted Astellas worldwide rights to develop and commercialize antibody-drug conjugates for cancer designed by Ambrx using its EuCODE site-specific protein chemistry technology

Ambrx Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Astellas Pharma Inc.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced